Immuneel is a pioneering clinical stage start-up company leading the change in cell & gene therapies & personalized immunotherapy for patients in India. Headquartered in Bengaluru, Karnataka, India, Immuneel is a research-led, fully integrated cell & gene therapies company committed to bringing breakthrough cancer treatments to India, affordably & build a portfolio of next generation cell therapies. Learn more at www.immuneel.com.
Location: India
Employees: 11-50
Total raised: $10.5M
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | F-Prime Ca... | fprimecapi... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.06.2026 | Series B | $10.5M | F-Prime Ca... |
Mentions in press and media 20
| Date | Title | Description |
| 08.06.2026 | Kiran Mazumdar-Shaw's Immuneel Therapeutics raises Rs 100 Cr in Series B funding | Immuneel Therapeutics, an integrated cell and gene therapy platform founded by Biocon founder Kiran Mazumdar-Shaw, has raised over Rs 100 crore in a Series B round of funding with participation from Singularity AMC, Rainmatter by Zerodha, a... |
| 08.06.2026 | Immuneel Therapeutics Raises ₹100 Cr To Take Its Gene Therapy For Blood Cancer Global | SUMMARY Bengaluru-based Immuneel Therapeutics has raised ₹100 Cr Series B fundraise from Singularity AMC, Rainmatter by Zerodha The round also saw participation from existing investors, including founder Kiran Mazumdar-Shaw, Eight Roads Ven... |
| 08.06.2026 | Kiran Mazumdar-Shaw's Immuneel Therapeutics raises Rs 100 crore from Singularity AMC, Rainmatter, others | Synopsis The Bengaluru-based company makes CAR-T therapy, a form of cancer treatment where a patientâs own immune cells are taken out, trained in a lab to fight cancer, and then put back into the body. The treatment has been seen as a maj... |
| 08.06.2026 | Eight Roads-backed Immuneel bags Series B funding for advanced cancer care | (Representative image) Immuneel Therapeutics, a cell and gene therapy startup co-founded by Biocon founder Kiran Mazumdar-Shaw, secured Series B funding to scale up its manufacturing capacity for cell therapy targeting a specific group of b... |
| 08.06.2026 | Immuneel eyes West Asia, Asia-Pacific expansion for cancer therapy after ₹100 crore funding | - |
| 08.06.2026 | Immuneel Therapeutics raises over Rs 100 crore to scale CAR-T cancer therapy, global expansion | Cancer-focused biotech startup Immuneel Therapeutics has raised more than Rs 100 crore in a Series B funding round to expand manufacturing, support the commercialisation of its CAR-T therapy and grow in overseas markets. Advertisment Singul... |
| 24.01.2025 | Kotak Alternate Asset Managers Marks First Close of INR 1,600 Cr Life Sciences Fund The fund aims to target early- to growth-stage companies across pharmaceuticals, biotechnology, medical devices, dig... | Kotak Alternate Asset Managers Ltd, a subsidiary of Kotak Mahindra Group, announced the first close of its Kotak Life Sciences Fund, a private equity vehicle aimed at India's healthcare and life sciences sector. The fund, sized at INR 1,600... |
| 21.09.2024 | The Future of Healthcare: Innovation and Collaboration at Pharmavision India 2024 | The healthcare landscape is shifting. At the forefront of this change is the 15th annual Pharmavision India conference, set to take place on September 25-26, 2024, in Ahmedabad and Hyderabad. This event is not just a gathering; it’s a cruci... |
| 18.09.2024 | Clarivate Announces 15th Annual Pharmavision India Conference Agenda | Industry leaders to discuss AI in healthcare, cell and gene therapy, market access and more at premier life sciences event LONDON, Sept. 18, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intellig... |
| 10.07.2024 | Exclusive: Kiran Mazumdar Shaw’s Immuneel Therapeutics raises Rs 100 Cr | Cancer focused biotech startup Immuneel Therapeutics has raised Rs 100 crore or $12 million in the extension of Series A round from Taiba Middle East FZ LLC. This is the third round of investment for the Bengaluru-based company since its in... |
Show more